Pfizer Q3 Eliquis Revenue Up 25% Operationally; Padcev Up 55%
Share
Why It Matters
Pfizer's blood thinner drug Eliquis and cancer medicine Padcev both sold much better this quarter. When a company's medicines sell really well, it shows doctors and patients trust them.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.